Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2023 · 10-Q
Revenue$270.50M$270.50M+12.8% vs Q3 2022 Net Income-$263.40M-$263.40MN/M vs Q3 2022 EPS Diluted-$5.08-$5.08N/M vs Q3 2022 Gross Profit$87,200,000+15.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$60,000,000N/M Free Cash Flowderived$47,400,000N/M Margins · derivedGross margin32.2%+0.8 pt vs Q3 2022
Operating margin-89.5%−70.6 pt vs Q3 2022
Net margin-97.4%−61.1 pt vs Q3 2022
ended Sep 30, 2023 · filed Dec 11, 2023 · 72 d after period end